Lead Sponsor

AstraZeneca

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•During the last 4 weeks prior to baseline, treatment with an inhaled steroid (dosage: up to 250 mcg fluticasone propionate or equivalent)
•FEV1 80 - 105% of predicted
•Healthy with the exception of asthma
•Written informed consent has been obtained
•Outpatients
•Patients who have a history of persistent bronchial asthma for at least 6 months

•Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids
•Concomitant COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function
•An asthma exacerbation or an infection of the lower airways prior to entry into the baseline period
•Pregnancy
•Intention to become pregnant during the course of the study
•Breast feeding
•Lack of safe contraception
•Patient is current smoker with 10 or more pack-years
•Patient is ex-smoker with 10 or more pack-years